Aronora, Inc.   Report issue

For profit Phase 2
Founded: Portland OR United States (2007)

Organization Overview

First Clinical Trial
2017
NCT03097341
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Aronora, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

e-we thrombin (2 trials)

xisomab 3g3 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Thrombosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2